MRC2 and triple-negative breast carcinoma: Equivalent levels of MRC2 expression are seen in CAFs isolated from oestrogen receptor positive (ER+), human epidermal growth factor receptor 2-positive (HER2+) or triple negative breast cancers (TNBCs) (Fig. 1f) indicating that the upregulated Endo180 expression in CAFs is not breast cancer subtype restricted.